Drug Discovery Featured Articles & Applications

  1. Oncology Drug Discovery Is Targeting The Wrong Problem 5/21/2026

    There is a growing tension between what we measure and what ultimately matters. This disconnect raises an uncomfortable but necessary question: are we targeting the right problem?

  2. Designing Data For Funding: Preclinical Development Strategies For Startups 5/20/2026

    Funding depends less on data volume and more on deliberate data staging to support key inflection points and enable pragmatic decision-making.

  3. Unfolding Protein & Antibody Discovery At PEGS 2026 5/19/2026

    Our editorial team covers the 2026 Protein & Antibody Engineering Summit (PEGS) in Boston -- A working map of where biologics R&D is headed.

  4. The Next Frontier In Women's Cancer Care: Combining Cell Therapy With Immuno-Oncology 5/19/2026

    The convergence of engineered cell therapies and immuno-oncology represents a significant step forward in the quest to improve outcomes for ovarian cancer patients.

  5. From Urine-Derived To Recombinant Precision: KLK1 Reimagined For Preeclampsia 5/8/2026

    DiaMedica is testing a synthetic, first-in-class recombinant human kallikrein‑1 (rhKLK1) biologic in Phase 2 clinical trials to treat preeclampsia, which remains one of the most dangerous complications of pregnancy.

  6. Executive Order For Psychedelics 5/8/2026

    We caught up with Joseph Tucker, Ph.D., CEO of Enveric Biosciences, to discuss the executive order for psychedelics.

  7. GLP-1 Receptor Agonists: Metabolism, Reward Biology, And AI-Driven Drug Discovery 5/6/2026

    For drug discovery teams, the central question is whether metabolic signaling pathways can serve as a tractable new entry point into addiction therapeutics.

  8. GLP-1 And Addiction: Mechanism, Missteps, And What Comes Next 5/4/2026

    Evidence suggests GLP-1R agonists may influence reward pathways and craving, raising important questions for addiction research and drug development.

  9. Regeneron Advances In Vivo Gene Therapy For Hearing Loss 5/1/2026

    Regeneron’s Otarmeni marks a major CGT milestone, showing that in vivo gene therapy can restore hearing in OTOF-related deafness while expanding the field’s clinical and delivery possibilities.

  10. GLP-1 Agonists In Addiction: Rationale And Drug Development 4/24/2026

    GLP-1 receptor agonists represent a scientifically credible and potentially consequential avenue in addiction medicine.